BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/16/2014 11:44:00 AM | Browse: 1291 | Download: 1059
 |
Received |
|
2012-10-17 10:59 |
|
Peer-Review Started |
|
2012-10-17 15:01 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2013-01-31 09:27 |
|
Revised |
|
|
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2013-03-15 18:04 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2013-03-15 23:19 |
|
Articles in Press |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2013-04-20 13:28 |
|
Publish the Manuscript Online |
|
2013-05-07 10:53 |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Tumor necrosis factor-α inhibitor therapy and fetal risk: A systematic literature review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Renée M Marchioni and Gary R Lichtenstein |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Gary R Lichtenstein, MD, Division of Gastroenterology, Hospital of the University of Pennsylvania, GI Administration Offices, 9th Floor Penn Tower, One Convention Avenue, PA 19104, United States. grl@uphs.upenn.edu |
| Key Words |
Tumor necrosis factor-α inhibitors; Pregnancy; Congenital abnormalities; Safety; Infliximab; Adalimumab; Certolizumab |
| Core Tip |
A systematic literature review was performed to identify all human studies with birth outcomes data after maternal exposure to infliximab, adalimumab, or certolizumab pegol within 3 mo of conception or during any trimester of pregnancy. After systematic literature review investigating tumor necrosis factor-α inhibitor therapy and fetal risk, there is insufficient evidence to prove absolute safety for the use of biologics (specifically infliximab, adalimumab, and certolizumab pegol) during pregnancy. |
| Publish Date |
2013-05-07 10:53 |
| Citation |
Marchioni RM, Lichtenstein GR. Tumor necrosis factor-α inhibitor therapy and fetal risk: A systematic literature review. World J Gastroenterol 2013; 19(17): 2591-2602 |
| URL |
http://www.wjgnet.com/1007-9327/full/v19/i17/2591.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v19.i17.2591 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
